3 not yet recruiting, 2 completed, 1 enrolling by invitation, 1 recruiting. 4 Phase 2, 3 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 1, Enrolling by invitation 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 3 | 3 | Not yet recruiting 2, Completed 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Cyclosporine (CsA): new trials by email Literature Review of Cyclosporine (CsA) trials Research Report on Cyclosporine (CsA)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TRACK-TBI Precision Medicine Part 3 - Option II Cyclosporine (CsA), Placebo - Traumatic Brain Injury | Phase 2 | Enrolling by invitation | University of California, San Francisco | 26 | 2026-07-02 | 2026-10-22 |
| CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAA Cyclosporine (CsA), Thrombopoietin Receptor Agonist, Romiplostim N01 - Severe Aplastic Anemia (SAA), Transfusion-dependent Non-severe Aplastic Anemia | Phase 2 | Withdrawn | Peking Union Medical College Hospital | 2026-06-01 | 2026-06-04 | |
| rhTPO + CsA vs CsA in the Treatment of LR-MDS With Thrombocytopenia rhTPO, Cyclosporine (CsA) - Lower-risk Myelodysplastic Syndromes | Phase 3 | Not yet recruiting | Peking Union Medical College Hospital | 78 | 2026-06-01 | 2026-06-17 |
| Enarodustat + CsA vs CsA in Newly Diagnosed TD-NSAA Enarodustat, Cyclosporine (CsA) - Transfusion-dependent Non-severe Aplastic Anemia | Phase 3 | Not yet recruiting | Peking Union Medical College Hospital | 90 | 2026-04-01 | 2026-04-23 |
| CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA Cyclosporine (CsA), thrombopoietin receptor agonist (TPO-RA), Romiplostim N01 - Severe Aplastic Anemia (SAA), Transfusion-dependent Non-severe Aplastic Anemia | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 43 | 2026-04-01 | 2026-04-30 |
| A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH Cytoxan, Etoposide, Dexamethasone - Hemophagocytic Syndrome | Not applicable | Recruiting | shifeng Lou | 160 | 2023-04-20 | 2023-08-30 |
| Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT) Cyclosporine (CsA), Belatacept LI (less intensive), Belatacept MI (more intensive) - Kidney Transplantation, Chronic Kidney Failure | Phase 3 | Completed | Bristol-Myers Squibb | 738 | 2005-03-01 | 2016-08-19 |
| Cyclosporine Dose Adjustment According to Calcineurin Activity After Allogeneic Hematopoietic Stem-cell Transplantation Dose adaptation according to CN activity monitoring, Cyclosporine (CsA) - Hematopoietic Stem Cell Transplantation, Graft Versus Host Disease | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 39 | 2004-01-01 | 2009-10-01 |
Anemia, Aplastic (2) · Brain Injuries, Traumatic (1) · Graft vs Host Disease (1) · Kidney Failure, Chronic (1) · Lymphohistiocytosis, Hemophagocytic (1)
Peking Union Medical College Hospital (4) · Assistance Publique - Hôpitaux de Paris (1) · Bristol-Myers Squibb (1) · University of California, San Francisco (1) · shifeng Lou (1)
France (2) · United States (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · China (1) · Czechia (1) · Germany (1) · Hungary (1) · India (1) · Israel (1) · Italy (1)
Geoffrey Manley, MD, PhD (1) · Hongbin Zhang, doctor (1) · Huaer Shu, bachelor (1) · Jinglong Lv, master (1) · Liang Fang, master (1) · Qing Wen, doctor (1) · Sylvia Sanquer, Pharm.D. (1) · Yizhi Xu, doctor (1) · Zailiang Yang, doctor (1)